1Tomany SC,Cruickshanks KJ,Klein R,et al.Sunlight and the 10-year incidence of ange-related maculopathy[J].Arch Ophthalmol,2004,122 (5):750-757.
2Hera R,Keramidas M,Peoch M,et al.Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration[J].Am J Ophthalmol,2005,139(4):589-596.
3Bhutto IA,Meleod DS,.Haseqawa T,et al.Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor(VEGF)in aged human choroid and eyes with age-related macular degeneration[J].Exp Eye Res,2006,82(1):99-110.
4Michels S,Rosenfeld PJ,Puliafito CA,et al.Systemic bevacizumab (avastin) therapy for neovascular age-related macular degeneration.Twelve-week results of an uncontrolled open-label clinical study[J].Ophthalmology,2005,112(6):1035-1047.
5Kaiser PK,Brown DM,Zhang K,et al.Ranibizumab for predominantly classic neovascular age-related macular degeneration:subgroup analysis of firsr-year ANCHOR Results[J].Am J Ophthalmol,2007,125 (10):1357-1361.
6Rosenfeld PJ,Schwartz SD,Blumenkranz MS,et al.Maximumtolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration[J].Ophthalmoligy,2005,112 (6):1048-1053.
7Wiegand ST,Thurston G,Stahl N,et al.VEGF Trap complex formation measures production rates of VEGF,providing a biomarker for predicting efficacious angiogenic blockade[J].Proc Natl Acad Sci USA,2007,13(12):1045-1049.
8Holash J,Wiegand SJ,Yancopoulos GD.New model of tumor angiogenesis:dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF[J].Oneogene,1999,18(38):5356-5362.
9Holekamp NM,Bouck N,Volpert AO.Pigment epitheliumderived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration[J].Am J Ophthalmol,2002,134 (2):220-227.
10Mason JO 3rd,Albert MA Jr,Persaud TO,et al.Intra vitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma[J].Retina,2007,27(1):903-907.
二级参考文献9
1翁维良 主编.活血化瘀治疗疑难病[M].北京:学苑出版社,2003.593-594.
2Bird A C, Bressler N M, Bressler S B, et al. An international classification and grading system for age - selated maculopathy and age - related maculardegeneration [J] .Surv Ophthalmol, 1995, 39 (5): 367-374.?A
3Klein R, Klein B E, Linton K L.Prevalence of age- related maculopathy [J] .Ophthalmology, 1992, 99 (6): 933-943.?A
5DnsaiRP, CiullaTA, PrattLM, et al.Intravitreal triamcinolone acetonide in exudative age- related macular degeneration [ J] .Retina,2000, 20 (3): 244-250.?A
6Yasukawa T, Kimura H, Tabata Y, et al. Active drug targeting with immunoconjugates to choroidal neovascularization [ J] . Curr Eye Res,2000, 21 (6): 952-961.?A
7Honda M, Sakamoto T, Ishibashi T, et al. Experimental subretinal neovascularization is inhibited by adenovirus - mediated soluble VEGF/flt - 1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age - related macular degeneration [ J ] . Gene Ther, 2000, 7(11): 978-985.?A
